Publications by authors named "F Davidovski"
Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have previously demonstrated cardioprotective properties in patients with type 2 diabetes, suggesting a preventive effect on heart failure (HF). The Empire Prevent trial program investigates the therapeutic potential for HF prevention by evaluating the cardiac, metabolic, and renal effects of the SGLT2 inhibitor empagliflozin in patients with increased risk of developing HF, but without diabetes or established HF.
Methods: The Empire Prevent trial program is an investigator-initiated, double-blind, randomized clinical trial program including elderly and obese patients (60-84 years, body mass index >28 kg/m) with at least one manifestation of hypertension, cardiovascular or chronic kidney disease, but no history of diabetes or HF.
Patients with chronic obstructive pulmonary disease (COPD) are prone to developing arterial hypertension, and many patients are treated with the calcium channel blocker amlodipine. However, it remains unclear whether using this drug potentially affects the risk of acute severe exacerbations (AECOPD) and all-cause mortality in these patients. The data were collected from Danish national registries, containing complete information on health, prescriptions, hospital admissions, and outpatient clinic visits.
View Article and Find Full Text PDFOral ketone esters acutely improve myocardial contractility in post-hospitalized COVID-19 patients: A randomized placebo-controlled double-blind crossover study.
Front Nutr
February 2023
Background: COVID-19 is associated with subclinical myocardial injury. Exogenous ketone esters acutely improve left myocardial function in healthy participants and patients with heart failure, but the effects have not been investigated in participants previously hospitalized for COVID-19.
Methods: This is a randomized placebo-controlled double-blind crossover study comparing a single oral ketone ester dose of 395 mg/kg with placebo.
Article Synopsis
- * In a study of 305 COVID-19 patients, lower GWI was found in patients with high levels of cardiac biomarkers, such as troponin and NT-proBNP, indicating worse cardiac function and a higher need for oxygen.
- * GWI was linked to an increased risk of death among patients, but it did not provide additional predictive value beyond existing clinical parameters like troponin and NT-proBNP levels.
Article Synopsis
- - A study assessed lung ultrasound (LUS) in COVID-19 patients before hospitalization and again 2-3 months after discharge, focusing on changes in lung findings over time.
- - Out of 71 patients studied, LUS findings showed a significant reduction in pathologic results from 87% during hospitalization to 30% at follow-up, with a notable decrease in B-lines.
- - Although improvements were observed, 28% of patients still had abnormal LUS findings at follow-up, especially those who experienced acute respiratory distress syndrome (ARDS), suggesting LUS is a valuable tool for ongoing monitoring of lung health in COVID-19 survivors.